Anterogen.Co.,Ltd.

A065660

KR7065660003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
15,910 ^KRW	-2.15%		+4.46%	-6.90%

2023	Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2021	Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment	CI

Anterogen Co., Ltd. has filed an IPO in the amount of KRW 13.20 billion.

January 05, 2016 at 12:00 am EST

Anterogen Co., Ltd. has filed an IPO in the amount of KRW 13.20 billion.

Offer Details:
Security Type: Common Stock
Offered: 600000
Price/Range: 17000.00 to 22000.00

Latest news about Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment	21-03-07	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment	21-03-04	CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding	20-04-23	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding	20-04-22	CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion.	20-03-25	CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm	19-11-06	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm	19-10-24	CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD.	19-02-25	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD.	19-02-14	CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding	19-01-31	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding	19-01-23	CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm	18-11-19	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor	18-11-07	CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm	18-10-30	CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm	18-10-03	CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding	18-06-11	CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from a group of investors.	18-06-10	CI
EM-Tech Co., Ltd. announced that it has received KRW 14 billion in funding from Anterogen Co.,Ltd.	18-04-10	CI
Anterogen Co.,Ltd. announced that it has received KRW 18 billion in funding	18-04-10	CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from Company K Partners Limited	17-09-28	CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from Company K Partners Limited	17-09-25	CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from EM-Tech. Co., Ltd.	17-04-26	CI
EM-Tech. Co., Ltd. announced that it has received KRW 7.82 billion in funding from Anterogen Co.,Ltd.	17-04-25	CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from EM-Tech. Co., Ltd.	17-04-24	CI

ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
ANTEROGEN.CO.,LTD.	-6.90%	113M
CSL LIMITED	+6.96%	98.81B
SAMSUNG BIOLOGICS CO.,LTD.	+7.24%	42.32B
BIOGEN INC.	-8.49%	34.48B
UCB	+83.52%	29.83B
BIOMARIN PHARMACEUTICAL INC.	-12.97%	15.93B
INCYTE CORPORATION	-0.80%	14.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.52B
ALTEOGEN INC.	+173.60%	10.45B
SWEDISH ORPHAN BIOVITRUM AB	+5.69%	9.06B